Overview

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

Status:
Terminated
Trial end date:
2019-01-02
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of PROHIBITIN-TP01 that can be given to patients with advanced prostate cancer for which there are no standard therapy options. The safety of this drug will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center